Seelos Therapeutics Inc (SEELQ)

[Dimitrios George]

>I don't understand where you can state that Apricus has a PIII for Femprox.

Well Zman, you might start by identifying where I stated that Apricus has a PIII for Femprox. I didn't. I was responding to a post that claimed Apricus was heading back for a PI.

What I got from the call and the presentation is that the FDA has not put up any major roadblocks in proceeding with Femprox development, that the company wants to see how Flibanserin is dealt with by the FDA and the company clearly wants a partner to pursue development.

Now do I think they are heading for a PIII either in the US or EU or both? Yes "I think" that. However, I do not feel they wanted to get into much of a discussion of how a PIII might be structured before they evaluate the Flibanserin decision. If you want to think something differently, fine.

For the record, a Femprox 98 patient PII study was conducted in the US prior to the China 400 patient studies.

And since your post seemed directed to me, I have never thought you to be short on Apricus, I have never to my knowledge implied that (here or elsewhere), I have always assumed you to be a long and frustrated shareholder underwater, just like me in that regard. I think I am a bit more patient than you are and I think that is reasonable considering this is a biotech with all the inherent risks in that sector. However, I appreciate your frustration. If Abbott had come through as we all hoped, I expect our conversations would be a lot different.